Extra-corporeal treatments like dialysis, and cardiopulmonary bypass, involve the circulation of the patient's blood supply through a machine. The patient's immune system treats the machine as a large, unwanted foreign body; the resulting inflammatory response contributes to a range of serious complications.
With its proprietary H-Guard™ biotechnology, Invizius is addressing the side effects of dialysis and other extra-corporeal treatments.
The business is a spin-out from world-class research carried out at the University of Edinburgh, Scotland, and has been funded by Scottish Enterprise's prestigious High-Growth Spinout Programme. Mercia Technologies is lead investor.
Priming solutions designed to alleviate the symptoms and complications of patients on extra-corporeal treatments
Our proprietary H-Guard™ coating is a potent anti-inflammatory and anti-coagulant, which cloaks surfaces from the human immune system
Our team combines world-leading scientists with experienced life science executives and entrepreneurs